Literature DB >> 8840276

Signal transduction of erythropoietin in endothelial cells.

H Haller1, C Christel, L Dannenberg, P Thiele, C Lindschau, F C Luft.   

Abstract

Erythropoietin (EPO) induces endothelin expression in endothelial cells (EC) and has angiogenic effects. We investigated the intracellular signal transduction of EPO in EC and tested the hypothesis that the proliferative effects of EPO may be mediated by cytosolic calcium, changes in intracellular pH, or tyrosine phosphorylation. Cytosolic calcium and pH were measured with fura-2 and BCECF. Protein phosphorylation was assessed with 32P-labeled EC and two-dimensional (2D) gel chromatography. Tyrosine phosphorylation was measured using specific antityrosine antibodies and confocal microscopy. Proliferation was measured by thymidine incorporation and cell count. No effects of EPO on cytosolic calcium and pH were observed. In contrast, erythropoietin increased phosphorylation of 94, 70, 42, 40, 29 and 25 kDa proteins at five minutes and 60 minutes. Most of the early proteins were tyrosine phosphorylated. Confocal microscopy showed cytosolic as well as membrane-bound tyrosine phosphorylation in resting cells and an EPO-induced translocation of immunoreactivity to the nucleus. Immunostaining for the transcription factor STAT-5 showed that EPO induced a nuclear translocation of STAT-5. EPO 0.5, 2, and 4 U/ml increased proliferation, an effect that was prevented by incubation with the tyrosine kinase inhibitor genistein. We conclude that EPO induces proliferation in EC initially via tyrosine phosphorylation of six distinct proteins, and that the phosphorylation and nuclear translocation of the transcription factor STAT-5 is important for the effects of EPO on EC.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8840276     DOI: 10.1038/ki.1996.339

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  13 in total

1.  An emerging cell-based strategy in orthopaedics: endothelial progenitor cells.

Authors:  Kivanc Atesok; Tomoyuki Matsumoto; Jon Karlsson; Takayuki Asahara; Anthony Atala; M Nedim Doral; Rene Verdonk; Ru Li; Emil Schemitsch
Journal:  Knee Surg Sports Traumatol Arthrosc       Date:  2012-03-09       Impact factor: 4.342

2.  Structural and functional effects of high prolactin levels on injured endothelial cells: evidence for an endothelial prolactin receptor.

Authors:  C J Merkle; L A Schuler; R C Schaeffer; J M Gribbon; D W Montgomery
Journal:  Endocrine       Date:  2000-08       Impact factor: 3.633

3.  Erythropoietin modulates intracellular calcium in a human neuroblastoma cell line.

Authors:  R Assandri; M Egger; M Gassmann; E Niggli; C Bauer; I Forster; A Gorlach
Journal:  J Physiol       Date:  1999-04-15       Impact factor: 5.182

4.  Dual Delivery of EPO and BMP2 from a Novel Modular Poly-ɛ-Caprolactone Construct to Increase the Bone Formation in Prefabricated Bone Flaps.

Authors:  Janki Jayesh Patel; Jane E Modes; Colleen L Flanagan; Paul H Krebsbach; Sean P Edwards; Scott J Hollister
Journal:  Tissue Eng Part C Methods       Date:  2015-07-22       Impact factor: 3.056

5.  Types of Erythropoietin-Stimulating Agents and Mortality among Patients Undergoing Hemodialysis.

Authors:  Yusuke Sakaguchi; Takayuki Hamano; Atsushi Wada; Ikuto Masakane
Journal:  J Am Soc Nephrol       Date:  2019-04-23       Impact factor: 10.121

6.  Recombinant human erythropoietin suppresses endothelial cell apoptosis and reduces the ratio of Bax to Bcl-2 proteins in the aortas of apolipoprotein E-deficient mice.

Authors:  Jeffrey S Warren; Ying Zhao; Raymond Yung; Anjali Desai
Journal:  J Cardiovasc Pharmacol       Date:  2011-04       Impact factor: 3.105

7.  Far-western blotting as a solution to the non-specificity of the anti-erythropoietin receptor antibody.

Authors:  Barbora Fecková; Patrícia Kimáková; Lenka Ilkovičová; Erika Szentpéteriová; Nataša Debeljak; Zuzana Solárová; Veronika Sačková; Martina Šemeláková; Mangesh Bhide; Peter Solár
Journal:  Oncol Lett       Date:  2016-06-24       Impact factor: 2.967

8.  Inhibition of erythropoietin signalling destroys xenografts of ovarian and uterine cancers in nude mice.

Authors:  Y Yasuda; T Musha; H Tanaka; Y Fujita; H Fujita; H Utsumi; T Matsuo; S Masuda; M Nagao; R Sasaki; Y Nakamura
Journal:  Br J Cancer       Date:  2001-03-23       Impact factor: 7.640

9.  Regulation of Erythropoietin Receptor Activity in Endothelial Cells by Different Erythropoietin (EPO) Derivatives: An in Vitro Study.

Authors:  Maria Letizia Trincavelli; Eleonora Da Pozzo; Osele Ciampi; Serena Cuboni; Simona Daniele; Maria Pia Abbracchio; Claudia Martini
Journal:  Int J Mol Sci       Date:  2013-01-24       Impact factor: 5.923

10.  Effects of recombinant human erythropoietin on revascularization of full thickness skin grafts in rat.

Authors:  Mohammad Javad Fatemi; Abol Hasan Emami; Sina Ghiasi; Seyed Morteza Seyed Jafari; Ali Akbar Mohammadi
Journal:  Iran Red Crescent Med J       Date:  2014-05-05       Impact factor: 0.611

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.